Sanofi says MS treatment reduced relapse rate
Home page > News

Sanofi says MS treatment reduced relapse rate

www.reuters.com   | 01.06.2012.

PARIS (Reuters) - Sanofi said on Friday that a trial of its multiple-sclerosis treatment teriflunomide found that a daily dose of the drug reduced the annualized rate of relapse by 36 percent compared with a placebo.
br />

Teriflunomide, marketed as Aubagio, is one of the two multiple sclerosis drugs Sanofi has in late-stage development and one of several oral MS treatments being developed by major drug companies.

(Reporting By Christian Plumb)


Comments (0) Add Your comment Add news < Previous news Next news >






  Add your news >>>